SCOT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是确定大剂量免疫抑制治疗后回输(移植)您自己的自体(自身)外周血干细胞(PBSCs)的安全性和有效性，与每月(12个月)静脉注射环磷酰胺(环磷酰胺，CTX)治疗严重系统性硬化症(SSC)的安全性和有效性进行比较。这些治疗是为了确定它们是否会减缓或阻止你的SSC变得更加严重，以及它们是否可以逆转疾病的影响。我们正在评估这两种治疗方法对与SSC相关的严重器官损伤和生存的影响，同时也观察这两种治疗方法的副作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to determine the safety and effectiveness of high-dose immunosuppressive therapy followed by reinfusion (transplantation) of your own autologous (self) peripheral blood stem cells (PBSCs) compared to treatment with monthly (for 12 months) intravenous doses of cyclophosphamide (Cytoxan, CTX) therapy for the treatment of severe systemic sclerosis (SSc). These treatments are being given in order to determine if they will slow down or stop your SSc from becoming more severe, and if they can reverse the effects of the disease. We are evaluating the effects of the two treatments on serious organ damage and survival related to SSc, while also looking at the side effects of the two treatments.